BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35062908)

  • 1. Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
    Chen W; Shan B; Zhou S; Yang H; Ye S
    BMC Cancer; 2022 Jan; 22(1):92. PubMed ID: 35062908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
    Chen W; Zhong S; Shan B; Zhou S; Wu X; Yang H; Ye S
    J Ovarian Res; 2020 Aug; 13(1):89. PubMed ID: 32771026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
    Ying J; Zhou D; Gu T; Huang J; Liu H
    BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer.
    Yu W; Ye Z; Fang X; Jiang X; Jiang Y
    J Ovarian Res; 2019 Sep; 12(1):88. PubMed ID: 31533857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
    Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
    BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
    Mahdi H; Maurer KA; Nutter B; Rose PG
    Int J Gynecol Cancer; 2015 Jun; 25(5):823-9. PubMed ID: 25828750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer.
    Rong Y; Li L
    J Ovarian Res; 2021 Jan; 14(1):2. PubMed ID: 33397458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
    Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
    Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.
    Chudecka-Głaz AM; Cymbaluk-Płoska AA; Menkiszak JL; Sompolska-Rzechuła AM; Tołoczko-Grabarek AI; Rzepka-Górska IA
    J Ovarian Res; 2014; 7():62. PubMed ID: 25018782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
    Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
    PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
    Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ; Lee IH; Kim YJ; Chung YS; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
    PLoS One; 2018; 13(9):e0203366. PubMed ID: 30188915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of human epididymis 4, D-dimer, and fibrinogen compared with CA 125 alone in triaging women presenting with pelvic masses: a retrospective cohort study.
    McKendry K; Duff S; Huang Y; Redha M; Scanlon Á; Abu Saadeh F; Gleeson N; O'Leary J; Norris L; O'Toole S
    Acta Obstet Gynecol Scand; 2021 Jul; 100(7):1239-1247. PubMed ID: 33590896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
    Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
    J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative Plasma Fibrinogen and D-dimer as Prognostic Biomarkers for Non-Muscle-Invasive Bladder Cancer.
    Li X; Shu K; Zhou J; Yu Q; Cui S; Liu J; Zhou R; Ding D
    Clin Genitourin Cancer; 2020 Feb; 18(1):11-19.e1. PubMed ID: 31787543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.